95 related articles for article (PubMed ID: 1979657)
1. Sustained-release (+)-PHNO [MK-458 (HPMC)] in the treatment of Parkinson's disease: evidence for tolerance to a selective D2-receptor agonist administered as a long-acting formulation.
Cedarbaum JM; Clark M; Toy LH; Green-Parsons A
Mov Disord; 1990; 5(4):298-303. PubMed ID: 1979657
[TBL] [Abstract][Full Text] [Related]
2. An open multicenter long-term treatment evaluation of Sinemet CR. Sinemet CR Multicenter Study Group.
Bush DF; Liss CL; Morton A
Neurology; 1989 Nov; 39(11 Suppl 2):101-4; discussion 105. PubMed ID: 2685646
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Sinemet CR4 and standard Sinemet: double blind and long-term open trial in parkinsonian patients with fluctuations.
Jankovic J; Schwartz K; Vander Linden C
Mov Disord; 1989; 4(4):303-9. PubMed ID: 2682215
[TBL] [Abstract][Full Text] [Related]
4. Effect of controlled-release carbidopa/levodopa on motor performance in advanced Parkinson's disease.
Rondot P; Ziegler M; Aymard N; Teinturier A
Neurology; 1989 Nov; 39(11 Suppl 2):74-7; discussion 95. PubMed ID: 2586765
[TBL] [Abstract][Full Text] [Related]
5. Long-term clinical efficacy of Sinemet CR in patients with Parkinson's disease.
Rodnitzky RL; Dickins QS; Dobson J
Neurology; 1989 Nov; 39(11 Suppl 2):92-5; discussion 95. PubMed ID: 2586769
[TBL] [Abstract][Full Text] [Related]
6. Controlled-release levodopa/carbidopa. III: Sinemet CR5 treatment of response fluctuations in Parkinson's disease.
Cedarbaum JM; Hoey M; Kutt H; McDowell FH
Clin Neuropharmacol; 1988 Apr; 11(2):168-73. PubMed ID: 3378225
[TBL] [Abstract][Full Text] [Related]
7. Treatment of early Parkinson's disease with controlled-release levodopa preparations.
Rinne UK; Rinne JO
Neurology; 1989 Nov; 39(11 Suppl 2):78-81; discussion 95. PubMed ID: 2586766
[TBL] [Abstract][Full Text] [Related]
8. Development and progression of motor fluctuations and side effects in Parkinson's disease: comparison of Sinemet CR versus carbidopa/levodopa.
Goetz CG; Tanner CM; Gilley DW; Klawans HL
Neurology; 1989 Nov; 39(11 Suppl 2):63-6; discussion 72-3. PubMed ID: 2586764
[TBL] [Abstract][Full Text] [Related]
9. Sinemet CR in the treatment of patients with Parkinson's disease already on long-term treatment with levodopa.
Aarli JA; Gilhus NE
Neurology; 1989 Nov; 39(11 Suppl 2):82-5; discussion 95. PubMed ID: 2586767
[TBL] [Abstract][Full Text] [Related]
10. Multicenter controlled study of Sinemet CR vs Sinemet (25/100) in advanced Parkinson's disease.
Hutton JT; Morris JL; Bush DF; Smith ME; Liss CL; Reines S
Neurology; 1989 Nov; 39(11 Suppl 2):67-72; discussion 72-3. PubMed ID: 2685652
[TBL] [Abstract][Full Text] [Related]
11. Off-period screaming accompanying motor fluctuations in Parkinson's disease.
Steiger MJ; Quinn NP; Toone B; Marsden CD
Mov Disord; 1991; 6(1):89-90. PubMed ID: 2005932
[No Abstract] [Full Text] [Related]
12. Trial of Sinemet CR4 in patients with Parkinson's disease.
Anderson TJ; Ewer TC; Gilchrist NL; Donaldson IM
N Z Med J; 1992 Mar; 105(929):81-2. PubMed ID: 1545941
[TBL] [Abstract][Full Text] [Related]
13. Double-blind comparison of standard Sinemet and Sinemet CR in patients with mild-to-moderate Parkinson's disease.
Feldman RG; Mosbach PA; Kelly MR; Thomas CA; Saint Hilaire MH
Neurology; 1989 Nov; 39(11 Suppl 2):96-101; discussion 105. PubMed ID: 2685655
[TBL] [Abstract][Full Text] [Related]
14. Antiparkinsonian activity of a single oral dose of PHNO.
Grandas F; Quinn N; Critchley P; Rohan A; Marsden CD; Stahl SM
Mov Disord; 1987; 2(1):47-51. PubMed ID: 2904120
[TBL] [Abstract][Full Text] [Related]
15. CV 205-502: safety, tolerance to, and efficacy of increasing doses in patients with Parkinson's disease in a double-blind, placebo crossover study.
Olanow CW; Werner EG; Gauger LL
Clin Neuropharmacol; 1989 Dec; 12(6):490-7. PubMed ID: 2575014
[TBL] [Abstract][Full Text] [Related]
16. Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies.
LeWitt PA; Nelson MV; Berchou RC; Galloway MP; Kesaree N; Kareti D; Schlick P
Neurology; 1989 Nov; 39(11 Suppl 2):45-53; discussion 59. PubMed ID: 2685650
[TBL] [Abstract][Full Text] [Related]
17. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies.
Yeh KC; August TF; Bush DF; Lasseter KC; Musson DG; Schwartz S; Smith ME; Titus DC
Neurology; 1989 Nov; 39(11 Suppl 2):25-38. PubMed ID: 2685649
[TBL] [Abstract][Full Text] [Related]
19. The antiparkinsonian actions and pharmacokinetics of transdermal (+)-4-propyl-9-hydroxynaphthoxazine (+PHNO): preliminary results.
Coleman RJ; Lange KW; Quinn NP; Loper AE; Bondi JV; Hichens M; Stahl SM; Marsden CD
Mov Disord; 1989; 4(2):129-38. PubMed ID: 2733705
[TBL] [Abstract][Full Text] [Related]
20. Controlled-release carbidopa-levodopa (Sinemet) in combination with standard Sinemet in advanced Parkinson's disease.
Mark MH; Sage JI
Ann Clin Lab Sci; 1989; 19(2):101-6. PubMed ID: 2665626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
